Drug intelligence / Profile preview

terfenadine

Development stage
Discontinued
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Terfenadine is a peripherally selective antihistamine that was formerly used for the treatment of allergic conditions such as seasonal and perennial allergic rhinitis, chronic urticaria (hives), and other histamine-mediated disorders. It acts as a reversible antagonist at the histamine H1 receptor in various tissues including the gastrointestinal tract, uterus, large blood vessels, and bronchial muscle. Terfenadine is a prodrug that is extensively metabolized in the liver to its active metabolite fexofenadine by cytochrome P450 3A4. Unlike many first-generation antihistamines, it does not readily cross the blood-brain barrier and thus has minimal central nervous system depressant effects. However, terfenadine itself can cause serious cardiac arrhythmias (notably QT interval prolongation and torsades de pointes) especially when taken with CYP3A4 inhibitors or in overdose situations; this led to its withdrawal from markets worldwide in the late 1990s[1][2][3][10].

Brand names
SeldaneTriludanTeldane
Other names
terfenadineSeldaneTriludanTeldane
02

Targets

KCNJ2 (Inward rectifier potassium channel Kir2.1)KCNJ4 (Inward rectifier potassium channel 2.3)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on terfenadine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on terfenadine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call